Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Wissenschaftlicher Artikel
Institutions
UKU. Klinik für Innere Medizin IIIPublished in
Lancet Oncology ; 19 (2018), 7. - S. 889-903. - ISSN 1470-2045. - eISSN 1474-5488
Link to publication
https://dx.doi.org/10.1016/S1470-2045(18)30240-7Funding information
Ambit Biosciences
Daiichi Sankyo
Daiichi Sankyo